{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:04:40Z","timestamp":1790949880163,"version":"4.1.0"},"reference-count":47,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>The rise in liver disease incidence and prevalence has led to increasing morbidity and mortality worldwide. Persistent hepatic inflammation drives disease progression by increasing fibrosis, advancing to cirrhosis, and potentially developing into hepatocellular carcinoma (HCC). Addressing these complications is essential to reduce liver-related mortality. Recent studies suggest that non-steroidal anti-inflammatory drugs, particularly aspirin, may play a beneficial role in managing liver disease. Aspirin\u2019s anti-inflammatory and chemoprotective effects contribute to slowing disease progression and reducing the risks associated with chronic liver disease (CLD). This review highlights the current literature on the effects of aspirin in CLD, with a focus on patients with metabolic-associated steatotic liver disease (MASLD) and hepatitis B and C. We will examine aspirin\u2019s potential ability to mitigate fibrosis, reduce the incidence of HCC, and lower liver-related mortality. Additionally, we will discuss its potential side effects and safety considerations, particularly in the context of liver disease, where there is an increased risk of bleeding.<\/jats:p>","DOI":"10.3390\/life14121701","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T05:58:27Z","timestamp":1734933507000},"page":"1701","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks"],"prefix":"10.3390","volume":"14","author":[{"given":"Amani","family":"Elshaer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca C.","family":"Lizaola-Mayo","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Transplant Hepatology, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis","volume":"18","author":"Moon","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_3","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1789\u20131858. Erratum in Lancet 2019, 393, e44."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3350\/cmh.2022.0186","article-title":"Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13515","article-title":"Aspirin use is associated with lower indices of liver fibrosis among adults in the United States","volume":"43","author":"Jiang","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","article-title":"Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality","volume":"382","author":"Simon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tacconelli, S., Contursi, A., Falcone, L., Mucci, M., D\u2019Agostino, I., Fullone, R., Sacco, A., Zucchelli, M., Bruno, A., and Ballerini, P. (2020). Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems. Biochem. Pharmacol., 178.","DOI":"10.1016\/j.bcp.2020.114094"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1021\/ja5112964","article-title":"Mechanistic Insights into a Classic Wonder Drug\u2014Aspirin","volume":"137","author":"Lei","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","article-title":"Use of Nonsteroidal Antiinflammatory Drugs","volume":"115","author":"Antman","year":"2007","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.cgh.2006.04.010","article-title":"Consensus Development Conference on the Use of Nonsteroidal Anti-Inflammatory Agents, Including Cyclooxygenase-2 Enzyme Inhibitors and Aspirin","volume":"4","author":"Wilcox","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1172\/JCI0214752","article-title":"Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II","volume":"110","author":"Qi","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1016\/S0002-9343(99)00115-1","article-title":"Role and regulation of cyclooxygenase-2 during inflammation","volume":"106","author":"Simon","year":"1999","journal-title":"Am. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1016\/S0002-9343(98)00069-2","article-title":"The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins","volume":"105","author":"Bjorkman","year":"1998","journal-title":"Am. J. Med."},{"key":"ref_14","first-page":"1033","article-title":"Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15R-prostaglandins that inhibit platelet aggregation","volume":"33","author":"Boeglin","year":"2018","journal-title":"FASEB J."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Jin, K., Qian, C., Lin, J., and Liu, B. (2023). Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1099811"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"174173","DOI":"10.1016\/j.ejphar.2021.174173","article-title":"Aspirin inhibits prostaglandins to prevents colon tumor formation via down-regulating Wnt production","volume":"906","author":"Feng","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1053\/j.gastro.2015.07.064","article-title":"Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice","volume":"149","author":"Wang","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIb\u03b1 is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.3350\/cmh.2022.0360","article-title":"Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma","volume":"29","author":"Cho","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_20","first-page":"1","article-title":"Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPAR\u03b4-AMPK-PGC-1\u03b1Pathway in Dyslipidemic Conditions","volume":"2020","author":"Han","year":"2020","journal-title":"BioMed Res. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-1458-8","article-title":"PPAR\u03b4 attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation","volume":"10","author":"Tong","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Fang, C., Pan, J., Qu, N., Lei, Y., Han, J., Zhang, J., and Han, D. (2022). The AMPK pathway in fatty liver disease. Front. Physiol., 13.","DOI":"10.3389\/fphys.2022.970292"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1210\/en.2010-1468","article-title":"The PPAR\u03b2\/\u03b4 Activator GW501516 Prevents the Down-Regulation of AMPK Caused by a High-Fat Diet in Liver and Amplifies the PGC-1\u03b1-Lipin 1-PPAR\u03b1 Pathway Leading to Increased Fatty Acid Oxidation","volume":"152","author":"Barroso","year":"2011","journal-title":"Endocrinology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1038\/onc.2017.73","article-title":"Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice","volume":"36","author":"Chen","year":"2017","journal-title":"Oncogene"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1053\/jhep.2002.36125","article-title":"Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells","volume":"36","author":"Kern","year":"2002","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1196\/annals.1322.052","article-title":"Induction of Apoptosis and Inhibition of Cell Growth in Human Hepatocellular Carcinoma Cells by COX-2 Inhibitors","volume":"1028","author":"Cusimano","year":"2004","journal-title":"Ann. New York Acad. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3892\/ijo.2011.1304","article-title":"Aspirin induces apoptosis in vitro and inhibits tumor growth of human hepatocellular carcinoma cells in a nude mouse xenograft model","volume":"40","author":"Hossain","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1001\/jama.2024.1215","article-title":"Aspirin for Metabolic Dysfunction\u2013Associated Steatotic Liver Disease Without Cirrhosis","volume":"331","author":"Simon","year":"2024","journal-title":"JAMA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis","volume":"19","author":"Stine","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.31121","article-title":"Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH","volume":"72","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1177\/1756283X16656735","article-title":"Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis","volume":"9","author":"Patel","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/HC9.0000000000000268","article-title":"Aspirin is associated with a reduced incidence of liver disease in men","volume":"7","author":"Vell","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.cgh.2019.04.061","article-title":"Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease","volume":"17","author":"Simon","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.32380","article-title":"Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis","volume":"76","author":"Jang","year":"2022","journal-title":"Hepatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1016\/j.cgh.2020.04.036","article-title":"Association of Daily Aspirin Therapy With Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis C Virus Infection","volume":"18","author":"Lee","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/apt.16515","article-title":"Systematic review with meta-analysis: The effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma","volume":"54","author":"Tan","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/jnci\/djs452","article-title":"Nonsteroidal Anti-inflammatory Drug Use, Chronic Liver Disease, and Hepatocellular Carcinoma","volume":"104","author":"Sahasrabuddhe","year":"2012","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/j.gastro.2019.03.070","article-title":"AGA Clinical Practice Update: Coagulation in Cirrhosis","volume":"157","author":"Greenberg","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.cgh.2023.04.016","article-title":"Bleeding and Thrombotic Complications in Patients With Cirrhosis: A State-of-the-Art Appraisal","volume":"21","author":"Rautou","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"73","author":"Northup","year":"2020","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/gutjnl-2020-321585","article-title":"Major GI bleeding in older persons using aspirin: Incidence and risk factors in the ASPREE randomised controlled trial","volume":"70","author":"Mahady","year":"2020","journal-title":"Gut"},{"key":"ref_43","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: A report of the american college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e00324","DOI":"10.14309\/ctg.0000000000000324","article-title":"Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog","volume":"12","author":"Hui","year":"2021","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ajg.2011.480","article-title":"Management of Patients With Ulcer Bleeding","volume":"107","author":"Laine","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/HEP.0000000000000671","article-title":"AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis","volume":"79","author":"Karvellas","year":"2024","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3350\/cmh.2021.0366","article-title":"Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?","volume":"28","author":"Goh","year":"2022","journal-title":"Clin. Mol. Hepatol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/12\/1701\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:58:21Z","timestamp":1760115501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/12\/1701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":47,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["life14121701"],"URL":"https:\/\/doi.org\/10.3390\/life14121701","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]}}}